Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while iShares MSCI United Kingdom (FTSE) trades at $48.33. The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EWU | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $48.68 |
52-Week Low | $0.48 | $40.90 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.33, down 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, with recent institutional activity showing mixed positions. Key support and resistance cluster around $48-$49, while RSI levels indicate neutral momentum. Geopolitical tensions and oil price volatility influence FTSE 100 performance, as highlighted in recent financial news.
The outlook for EWU is cautiously optimistic, supported by technical strength but tempered by macroeconomic risks. Opportunities include exposure to UK market resilience, while risks involve Middle East tensions and inflation concerns. Investors should weigh institutional inflows against broader market volatility for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
